Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

Drug resistant tuberculosis contributes significantly to the global burden of antimicrobial
resistance, often consuming a large proportion of the healthcare budget and associated …

Background Tuberculosis is the world's leading infectious disease killer. We aimed to
identify shorter, safer drug regimens for the treatment of tuberculosis. Methods We did a …

Tuberculosis (TB) recently became the leading infectious cause of death in adults, while
attempts to shorten therapy have largely failed. Dormancy, persistence, and drug tolerance …

Tuberculosis (TB) remains a devastating disease, yet despite its enormous toll on global
health, tools to control TB are insufficient and often outdated. TB Biomarkers (TB‐BM) would …

A burgeoning epidemic of drug-resistant tuberculosis (TB) threatens to derail global control
efforts. Although the mechanisms remain poorly clarified, drug-resistant strains are widely …

The manual observation of sputum smears by fluorescence microscopy for the diagnosis
and treatment monitoring of patients with tuberculosis (TB) is a laborious and subjective …

Lipid species play a critical role in the growth and virulence expression of Mycobacterium
tuberculosis (Mtb), the causative agent of tuberculosis (TB). During Mtb infection, foamy …

Tuberculosis remains a threat to global health and recent attempts to shorten therapy have
not succeeded mainly due to cases of clinical relapse. This has focussed attention on the …

Antibiotic treatment of tuberculosis has a duration of several months. There is significant
variability of the host immune response and the pharmacokinetic-pharmacodynamic …